Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | CHIEF BUSINESS OFFICER | April 09, 2026 | April 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date April 09, 2026 · Filed April 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.29 · Expires 2036-04-08 | Direct | 250,000 |
Reported balance
After 2026-04-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-09 · Grant · Acquired 250,000 · Balance 250,000 F1: This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 09, 2026 Filed Apr 10, 2026 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001193125-26-151201 · ownership.xml · derivative · entry 1 Warren Lucinda · CIK 0002035620 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2036-04-08 F1 · derivative.exercise_date: This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter. Read SEC document |
| September 29, 2025 Filed Nov 25, 2025 21:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001193125-25-296986 · ownership.xml · derivative · entry 1 Warren Lucinda · CIK 0002035620 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-09-28 F1 · derivative.exercise_date: This stock option becomes fully exercisable on the first anniversary of the grant date. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0000950170-25-044344 · ownership.xml · derivative · entry 1 Warren Lucinda · CIK 0002035620 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2035-03-20 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0000950170-24-103955 · ownership.xml · derivative · entry 1 Warren Lucinda · CIK 0002035620 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2034-09-02 F1 · derivative.exercise_date: This stock option becomes exercisable in four equal semi-annual installments beginning on March 3, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.